At Inotek, our focus is defining the future of eye care. We’re dedicated to using medical research and scientific innovation to restore and protect the vision of those suffering from diseases of the eye. With the groundbreaking discovery of trabodenoson, we’re ready to offer a pressure relieving solution for the eye with minimal side effects and no painful injections.
- Inotek Pharmaceuticals Announces the Completion of the Recruitment Phase of MATrX-1, the First Phase 3 Clinical Trial of Trabodenoson for Glaucoma Read Full Press Release
- Inotek Pharmaceuticals Appoints Patrick Machado, JD, to Board of Directors Read Full Press Release
- Inotek Pharmaceuticals Corporation Reports Second Quarter 2016 Financial Results and Operational Highlights Read Full Press Release
- Inotek Pharmaceuticals Phase 3 Development Plhan Conference Call Webcast Visit the Webcast Archive